Special Situations/Distressed • Life Science

NKGen Acquires NKMax

On September 9, 2025, NKGen acquired life science company NKMax

Acquisition Context

This is NKGen’s 1st transaction in the Life Science sector.
This is NKGen’s 1st transaction in South Korea.

Explore All 18 Special Situations/Distressed Life Science Deals - Search the Database Free

M&A Deal Summary
Date	September 9, 2025
Target	NKMax
Sector	Life Science
Buyer(s)	NKGen
Deal Type	Special Situations/Distressed

Target Company

NKMax

Seongnam-si, South Korea

NKMax is a biotechnology company that provides specialized immune healthcare solutions from diagnosis to treatment. It developed the NK Vue Kit, a precision immune diagnostic kit that measures immunity based on research on NK cells, which serve as the body's first line of defense. NKMax was formed in 2002 and is based in Seongnam-si, South Korea.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

NKGen

Santa Ana, California, United States

Category	Company
Sector	Life Science

DESCRIPTION

NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Special Situations/Distressed	1 of 1
Country: South Korea	1 of 1
Year: 2025	1 of 1

Explore Related M&A Activity

Life Science M&A - Special Situations/Distressed M&A Deals - South Korea M&A - 2025 M&A